Article citationsMore>>
Lee, T., Laco, G., Torbett, B., Fox, H., Lerner, D., Elder, J. and Wong, C. (1998) Analysis of the S3 and S3’ Subsite Specificities of Feline Immunodeficiency Virus (FIV) Protease: Development of a Broad-Based Protease Inhibitor Efficacious against FIV, SIV, and HIV In Vitro and Ex Vivo. Proceeding of the National Academy of Science, 95, 939-944. https://doi.org/10.1073/pnas.95.3.939
has been cited by the following article:
-
TITLE:
Synthesis of a New Lopinavir Phosphinic Analog as HIV-1 Inhibitor
AUTHORS:
Ruba Kellow, Magdalini Matziari
KEYWORDS:
HIV-1, Lopinavir, PL1
JOURNAL NAME:
Journal of Materials Science and Chemical Engineering,
Vol.7 No.7,
July
10,
2019
ABSTRACT: HIV/AIDS has been one of the most devastating global diseases. HIV-1 protease proteolytic action is responsible for the manufacture of grown, infectious species, consequently HIV-1 protease has become an attractive goal in the treatment and therapy of HIV. Several HIV-1 protease inhibitors based therapeutic agents are under investigation or currently in the market. Lopinavir (ABT-378) has a great value in this research field. Therefore, different methods have appeared aiming to develop efficient analogs by the utilization of variable techniques, since Lopinavir had showed low bioavailability when being prescribed alone, and various side effects after the combination of Lopinavir with another HIV-1 inhibitors such as Ritonavir, which is available in the markets nowadays under the brand name Kaletra. Replacement of the hydroxyethylene moiety in Lopinavir structure, which is responsible for the monohydroxylated metabolites with the stable to hydrolysis phosphinic group has been considered, since that hydroxyl group in the central core is responsible for the interaction with the carboxylic acid in the catalytic aspartyl residue of HIV-1 by hydrogen bonding and consequently supports the drug affinity to the protease. The small scale processes for the synthetic strategies for the new candidate phosphinic analog of Lopinavir protease inhibitor (PL1) is presented here in along with some preliminary pharmacological data.